Cell proliferation and invasion are critical for malignant progression, yet how these processes relate to each other and whether they regulate one another during metastasis is unknown. We show that invasiveness of breast cancer cells is associated with growth arrest due to p21CIP1 upregulation. Knockdown of p21CIP1 increases cell proliferation and suppresses invasion. Since p21CIP1 acts to inhibit cyclin E during cell-cycle progression, we demonstrated that a constitutively active form of cyclin E had similar effects to p21CIP1 inhibition resulting in enhanced cell growth and suppressed invasiveness. We tested these findings in vivo in the Polyoma middle T mammary tumor model in which p21CIP1 was deleted. p21CIP1 knockout mice exhibited dramatic suppression of metastasis, independent of tumor growth, which was rescued by p21CIP1. Metastasis suppression by p21CIP1 ablation was associated with striking cytoskeletal reorganization leading to a non-invasive and highly proliferative state. Thus, p21CIP1 regulates metastasis by mediating reciprocal switching between invasion and proliferation.
INTRODUCTION
Tumor cells are genomically unstable and hence prone to mutations that cause the development of aggressive phenotypes leading to metastasis. 1, 2 Checkpoints that control cell-cycle progression are believed to be critical for genomic stability. p21CIP1/WAF1 is a cell cycle-dependent kinase inhibitor implicated in G1 arrest. It interacts with, and inactivates, cyclin E-CDK2 complexes that are essential for G1-to-S phase transition. 3, 4 p21CIP1 is also a downstream target of p53, which is induced by DNA damage to prevent replication of damaged DNA. 5, 6 p21CIP1 is best known for its role in cell-cycle arrest in G1 but it may also block proliferating cell nuclear antigen (PCNA) during S phase to further delay DNA synthesis and repair DNA. 7 Derailed cell-cycle checkpoints resulting from mutations that inactivate associated tumor suppressors, cell-cycle inhibitors, or activate cyclins, can lead to aberrant proliferation and genomic instability resulting in malignant transformation. 8 Hallmarks of tumor cells also include their ability to migrate and invade. 1 While proliferation and invasion are critical for malignant progression, little is known about how the two processes relate to each other and whether they regulate one another during metastasis. It appears that invasion and proliferation may exclude one another under normal or pathological conditions. During development, neural crest cells undergo epithelial-to-mesenchymal transition (EMT), and hence cell migration, a process that is associated with cyclin D2 repression, p21CIP1 upregulation, leading to cell-cycle arrest. 9 Similarly during EMT tumor cells undergo profound cytoskeletal changes that support motogenesis but suppress mitogenesis, 10 implying a mutually exclusive relationship between these processes.
There are conflicting views on the role of p21CIP1 in invasion and metastasis. Some studies showed an upregulation of p21CIP1 in invasive breast cancers and a correlation between p21CIP1 expression and poor survival. 11, 12 Others have shown that expression of the cytosolic Akt-phosphorylated form of p21CIP1 in the mammary epithelium of MMTV-neu mice accelerated tumor progression, implying an oncogenic role for p21CIP1 in the cytoplasm, which differentiates it from its anti-proliferative role in the nucleus. 13 Cytoplasmic p21CIP1 is thought to promote malignancy by inhibiting the Rho kinase/LIMK pathway, resulting in cofillin phosphorylation, actin depolymerization and impaired cell migration. 14 In contrast, another study showed that p21CIP1 knockdown in Ras-transformed MCF10A cells caused EMT and induced stem-like properties when knocked out in MMTV-Ras and MMTV-Myc transgenic mice, suggesting that p21CIP1 acts as a malignancy suppressor. 15 To address the roles of p21CIP1 in cell proliferation versus metastasis, we crossed the Polyoma Middle T (PyMT) mammary tumor model of metastasis, 16 to the p21CIP1 knockout (p21KO) mouse. 17 PyMT/p21KO mice had dramatic reductions in pulmonary metastasis relative to PyMT control mice. PyMT/p21KO tumors exhibited suppressed invasion in vivo and in vitro. Similarly, knockdown of p21CIP1 or activated cyclin E expression in human breast cancer cell lines increased proliferation and suppressed invasion. p21CIP1 loss or variant cyclin E expression caused striking cytoskeletal reorganization from stress fibers to cortical actin, upregulation of cytokeratins and gain in cell polarity. We conclude that p21CIP1 loss suppresses metastasis by inhibiting alternate switching between invasion and proliferation.
RESULTS

Invasion is accompanied by p21CIP1 stabilization and cell-cycle arrest in G1
To begin study the relationship between cellular invasion and proliferation in breast cancer metastasis, we used a model for epithelial invasiveness in which N-cadherin was expressed in MCF-7 breast cancer cells (MCF-7-N-cad). When injected into the mammary fat pads of athymic mice, MCF-7-N-cad cells were highly metastatic as compared to MCF-7 control cells. 18 Interestingly, despite being metastatic, MCF-7-N-cad mammary tumors were smaller than MCF-7 tumors, suggesting conditions that promote metastasis may suppress tumorigenesis. 18 Treatment of MCF-7-N-cad cells with FGF-2 further enhanced invasiveness due to FGF receptor potentiation by N-cadherin. 19 FGF-2 also caused a dramatic suppression of cell proliferation as shown by a sharp (sevenfold) reduction in BrdU incorporation in MCF-7-N-cad cells relative to untreated cells (Figure 1a , right panels). By contrast, FGF-2 slightly increased BrdU intake in MCF-7 cells (Figure 1a , left panels). Moreover, FACS-based DNA content analysis showed striking differences in cell-cycle progression. FGF-2 caused B50% of the MCF-7 cells to re-enter the cell cycle into S phase by 24 h, in contrast to MCF-7-N-cad cells which became almost completely arrested in G1 by 24 h (Figure 1b ). This coincided with the time where cells were most invasive. 19 Consistent with a G1 arrest, FGF-2 significantly increased p21CIP1 expression in MCF-7-N-cad cells relative to MCF-7 cells (Figure 1c) , which was mostly present Figure 1 . FGF-2-induced invasion causes p21CIP1 upregulation and a G1 cell-cycle arrest. (a) Control MCF-7 or MCF-7-N-cad cells were untreated (first and third panels) or treated (second and fourth panels) with 50 ng/ml FGF-2 for 24 h and pulsed with BrdU 1 h before ending the experiment. Cells were then fixed and stained with anti FITC-BrdU antibody and DAPI to visualize nuclei. (b) Cell-cycle kinetics were examined in control MCF-7 and MCF-7-N-cad cells. MCF-7 cells (left) or MCF-7-N-cad (right) were grown in 10% fetal bovine serum or serum starved for 12 h. Serum-starved cells were treated with FGF-2 for 3, 6, 12, 24 and 36 h. Cells were harvested, fixed and stained with propidium iodide. DNA content was analyzed by FACS. G1, S-and G2-M phase cells are indicated. Data are displayed as percent cells as a function of time in hours. 'FBS' indicates random cycling cells with no serum deprivation or growth factor treatment. (c) MCF-7 or MCF-7-N-cad cells were serum starved for 12 h and treated with 50 ng/ml FGF-2 for the indicated times. Cell lysates were immunoblotted with anti-p21
Cip1
, p27
KIP1 or a-tubulin antibody. (d) MCF-7 or MCF-7-N-cad cells were untreated (first and third panels) or treated with 50 ng/ml FGF-2 for 16 h (second and fourth panels), fixed and stained with anti-p21
Cip1 and DAPI.
p21CIP1 promotes mammary tumor metastasis X Qian et al in the nucleus (Figure 1d ). By contrast, the levels of p27KIP1 were unchanged by FGF-2 in both cell lines (Figure 1c ). p21CIP1 upregulation was due to transcription as shown by increased p21CIP1 promoter luciferase reporter activity and a 4.5-fold increase in mRNA levels in FGF-2 stimulated MCF-7-N-cad cells relative to untreated cells or to MCF-7 control cells (Supplementary Figure 1) . These results suggest that p21CIP1 might be important for the invasiveness of MCF-7-N-cad cells. 19 To confirm the role of p21CIP1 in the inverse relationship between proliferation and invasion, we used MCF10A cells that undergo EMT and migration in response to TGFb. Indeed, treatment of MCF10A with TGFb for 1 and 2 days caused a linear increase in p21CIP1 but had no effect on p27KIP1 expression (Figure 2a) . Moreover, TGFb-stimulated increases in p21CIP1 were accompanied by increased Matrigel invasiveness (Figure 2b ) and decreased cell proliferation as shown by BrdU incorporation (Figure 2d ). Staining of MCF10A cells with anti-p21CIP1 or antiBrdU antibody showed increased p21CIP1 and decreased BrdU staining in nuclei of TGFb-treated cells relative to control untreated cells (Figures 2c and d) . Furthermore, siRNA knockdown of p21CIP1 in MCF10A cells reduced constitutive and TGFb stimulated invasion in Matrigel, suggesting an active role for p21CIP1 in the growth arrest accompanying cellular invasion ( Figure 2e ). p21CIP1 is required for movement of cellular processes and cell migration To further examine the requirement for p21CIP1 for cell migration and invasion, we silenced p21CIP1 in MCF-7-N-cad cells using siRNA (Figure 3a) . To test whether the effects of p21CIP1 on cell motility were effective through a range of tumor cell aggressiveness, we also knocked down p21CIP1 in the malignant breast cancer MDA-MB-231 (MDA-231) cell line and its lung metastatic subline, 3475 20 ( Figures 3b and c, left) . Immunoblotting and immunofluorescent staining for p21CIP1 showed that p21CIP1 expression was totally suppressed (Figures 3a-c) and was efficiently excluded from the nuclei of all three cell lines (Supplementary Figure 2a) . Moreover, p21 knockdown resulted in greatly suppressed cell migration and invasion in all breast cancer cell lines (Figures 3a-c, middle) . The pro-motility effect of p21CIP1 was correlated with its anti-proliferative effect as p21CIP1 knockdown cells had increased BrdU incorporation levels relative to control cells (Figures 3a-c, right) . These effects were confirmed following stable knockdown of p21CIP1 using lentiviral shRNA infection in MDA-231 and 3475 cells (Supplementary Figure 3) .
Because transwell assays measure end point migration, we also evaluated the effect of p21CIP1 siRNA on epidermal growth factor (EGF)-stimulated cell motility using time-lapse video microscopy as no cellular movement was detected in the absence of EGF treatment of MDA-231 or 3475 cells (data not shown). While control MDA-231 cells exhibited cellular processes of different lengths that responded to EGF through outgrowth and retraction (N ¼ 5, 20 cells/experiment), p21CIP1 knockdown cells formed shorter protrusions that were refractory to EGF (Supplementary Figure 4a) . Similar effects were seen in 3475 cells; control cells displayed varying process lengths (Supplementary Figure 4c) whereas p21CIP1 knockdowns formed protrusions that did not move in response to EGF (Supplementary Figure 4c) . Measurements of cell migration over 30 min time confirmed these data; MDA-231 and 3475 cells migrated B17 and B24 mm, respectively, whereas p21CIP1-deficient cells did not move in response to EGF ( Supplementary Figures 4b and d) . Consistent with these data, vinculin staining revealed that MDA-231 and 3475 control cells formed protrusions with elaborate focal adhesions whereas p21CIP1 knockdown exhibited aberrant ECM contacts (Supplementary Figures 4b and d) .
Cyclin E enhances cell proliferation and attenuates migration and invasion These results suggested that p21CIP1 affects cell migration, but the mechanism remained unknown. One possibility is that p21CIP1 promotes motility by suppressing proliferation. To test the reciprocity of these events, we utilized a constitutively active amino-terminal truncated cyclin E, known as 'Trunk', which is missing its p21CIP1-binding domain and causes deregulated cell proliferation. 21 Trunk expression in MDA-231 and 3475 cells accelerated cell growth in both cell lines compared with control vector transfectants (Figures 4a and b Figure 2d) . These data suggest that cells undergoing uncontrolled proliferation are unable to exert migration or invasion likely due to conflicting cytoskeletal states.
To address in vivo the effect of mutant cyclin E-induced increases in cell proliferation on cellular invasion, we tested the invasiveness of primary tumors formed by control and 3475-Trunk cells following injection into mammary fat pads of athymic mice. We used an in-vivo invasion assay in which tumor cells are stimulated to migrate away from the primary tumor into microneedles loaded with EGF and Matrigel. 22 In this assay, the needles are inserted into the primary tumors of anesthetized mice for 3 h and epithelial cells migrating into the needles in response to buffer versus EGF are counted. Interestingly, we found that 3475-Trunk tumors were substantially less invasive (B10-fold) than 3475 control tumors in response to EGF (Figure 4g ). These data demonstrate that hyperproliferation suppresses migration and invasion in vitro and in vivo.
p21CIP1 knockout suppresses invasion and metastasis in vivo
To examine whether the loss of p21CIP1 cell-cycle control affects metastasis in vivo, we crossed the PyMT mammary tumor model of breast cancer metastasis, 16 to the p21CIP1 knockout mouse. 17 We compared PyMT mice with PyMT/p21KO mice of identical genetic background for lung metastasis and mammary tumor growth at various times following tumor onset (12 weeks of age). Control PyMT mice generated extensive pulmonary metastasis (from 37 to 120 nodules in the lung per mouse), whereas PyMT/p21KO mice produced only B2-6 lung foci at 10-13 weeks post tumor onset, hence a 20-fold suppression (Figure 5a ). These data demonstrate an unexpected pro-metastatic function of p21CIP1 in light of its putative growth suppressive function.
To address whether suppression of metastasis was caused by a defect in tumor invasiveness, we used an in-vivo invasion assay that measures chemotaxis of tumor cells toward EGF in the primary tumor. 22 We found that PyMT/p21KO primary tumors showed reduced EGF-induced invasion; relatively few tumor cells migrated into the needles relative to PyMT control cells (Figure 5b ). These results support a potential inverse relationship between tumor cell growth and invasion, implying p21CIP1 facilitates switching between the two states.
To evaluate the effects of p21CIP1 ablation on tumor formation, we measured kinetics of primary tumor growth by measuring tumor burden. However, since tumors grew in a multinodal p21CIP1 promotes mammary tumor metastasis X Qian et al pattern, we combined the mass of individual tumors (aggregate tumor mass) ( Figure 5c) . Surprisingly, we found that PyMT/p21KO mice exhibited a mild reduction in tumor burden relative to PyMT mice ( Figure 5c ). However, scatter plot analysis of the relationship between tumor mass and metastatic index showed that PyMT/p21KO mice were unable to metastasize at tumor sizes for which wild-type tumors were highly metastatic, suggesting that the reduced mass cannot account for the striking suppression of metastasis (Figure 5d ). Indeed, carcinoma cell proliferation in vivo, as measured by PCNA immunohistochemistry, showed a clear increase in cell proliferation in PyMT/P21KO tumors compared with wild-type PyMT controls (Figure 5e ). The number of Since p21CIP1 is known to protect cells against apoptosis, 4 we ruled out a potential effect of p21CIP1 loss on apoptosis that might have contributed to reduced tumor mass. We measured apoptosis in primary tumors from PyMT and PyMT/p21KO mice using the TUNEL assay. The level of apoptosis was however unchanged between the two mouse genotypes (Supplementary Figure 5a) . Additional factors that regulate tumor growth involve tumor angiogenesis; however, examination of vessel density in primary tumors using anti-CD34 immunohistochemistry did not reveal any changes in angiogenesis between PyMT and PyMT/ p21KO tumors (Supplementary Figure 5b) . Finally, to rule out whether p21CIP1 deficiency in the host microenvironment affects lung colonization and thus metastasis, we injected equal numbers of PyMT/p21KO or PyMT tumor cells into the tail vein of athymic mice which are p21CIP1 competent. As in transgenic mice, PyMT/ p21KO tumor cells were unable to colonize the lungs relative to PyMT controls that greatly colonized the lungs of recipient mice (Supplementary Figure 5c) . Thus, p21CIP1 loss conveys a tumor cell-autonomous defect that impairs metastasis.
p21CIP1 deletion enhances proliferation and suppresses invasion in vitro and in vivo We next determined whether the loss of p21CIP1 affects tumor cell growth in vitro. We isolated epithelial cell lines from PyMT and PyMT/p21KO mammary tumors and confirmed their p21CIP1 status and epithelial origin using anti p21CIP1 or anti E-cadherin immunoblotting ( Figure 6a ). We next measured growth rates of the cell lines for 8 days in culture. We found that PyMT/p21KO cells grew substantially faster than PyMT cell lines (Figure 6b ), thus confirming the growth inhibitory function of p21CIP1. To determine if hyperproliferation affects cellular invasion in these cell lines, we gauged the migration of PyMT and PyMT/p21KO tumor cell lines in vitro in a 5-h transwell motility assay. The mobility of all PyMT/p21KO cell lines was dramatically reduced compared with the highly motile PyMT cells (Figure 6c) . Moreover, transfection of p21CIP1 into PyMT/p21KO cells rescued cell motility (Figure 6d ) and reduced growth rates (Figure 6e) . Furthermore, p21CIP1 rescue also restored lung colonization which was measured following tail-vein injection of tumor cells into athymic mice. Remarkably, p21CIP1-transfected PyMT/p21KO cells generated 18 foci per lung section as compared with 20 foci by PyMT cells and none by PyMT/p21KO cells (Figures  6f and g ). p21CIP1 loss causes cytoskeletal reorganization leading to epithelial differentiation We sought to determine whether the switch from a motile to a non-motile tumor cell type caused by p21CIP1 deletion was associated with changes in the cytoskeleton. We found that compared with PyMT tumor cells that formed striking actin stress fibers, PyMT/p21KO cells exhibited cortical actin (Figure 7a, left) , indicating increased cortical rigidity conforming with a non-motile phenotype. Moreover, staining with anti-vinculin revealed marked changes in ECM adhesion; PyMT cells formed elaborate focal Figure 4) . Furthermore, staining of PyMT/p21KO cells for ZO-1 revealed enhanced cell polarity as shown by the contiguous junctional lining by ZO-1 relative to irregular staining in PyMT cells (Figure 7a, right) . Interestingly, these cytoskeletal changes were associated with a transition from a proliferative to a non-motile state (see Figures 6b and c) . These data further suggested that p21CIP1 knockout induces epithelial differentiation. Indeed, we found a dramatic upregulation of pan-cytokeratin in knockout cells relative to PyMT cells, as shown by immunostaining and immunoblotting (Figure 7b, left) . Densitometric analysis confirmed a fivefold increase in pan-cytokeratin levels in PyMT/ p21KO over PyMT cells (Figure 7c ). These data were also confirmed in vivo; PyMT/p21KO mammary tumors exhibited increased pan-cytokeratin immunostaining (Figure 7b , right) and a 2.5-fold increase in pan-cytokeratin levels relative to PyMT controls (Figure 7d ). Interestingly, active cyclin E (Trunk) expression in MDA-231 cells, that reduced invasion while enhancing cell proliferation, was also accompanied by remodeling of the actin cytoskeleton. Consistent with the effect of p21CIP1 knockout in PyMT mammary tumor cells, Trunk expression in MDA-231 cells caused a gain in cortical actin, increased pan-cytokeratin and junctional ZO-1 expression (Supplementary Figure 2d) . Thus, the inhibitory effect of p21CIP1 knockout or active cyclin E on the invasive phenotype is supported by changes in the cytoskeleton to accommodate switching between cell migration and cell division.
DISCUSSION
It is conventionally thought that metastasis develops at least partly as a function of tumor growth. Indeed, tumor size is an unfavorable prognostic marker in breast cancer, implying metastasis develops as a result of tumor cell hyperproliferation. 23 While cell growth and invasion contribute to malignant progression, these processes are likely to be mutually exclusive. Reciprocal switching between these events involves differential gene expression that facilitates cell-cycle progression while inhibiting invasion and vice versa. In support of this notion, studies of invasive tumor cell populations in vivo have shown that motile cells upregulate genes that support invasion while attenuating those promoting proliferation. 24 We speculate that p21CIP1 expression in vivo might be regulated in a spatial-temporal manner in response to chemotactic p21CIP1 promotes mammary tumor metastasis X Qian et al or mitogenic stimuli from the tumor microenvironment. It is thus likely that carcinoma cells at the tumor-stroma interface may be prone to changes in p21CIP1 expression relative to cells in the bulk of the tumor. Hence, cues from the tumor microenvironment may modulate p21CIP1 expression to tilt the balance toward invasive or proliferative growth. Indeed, we showed that p21CIP1 expression was induced by motogenic growth factors such as FGF-2 or TGFb. Stimulation of breast cells with either chemokine stimulated invasion but suppressed proliferation, suggesting that tumor cells must growth arrest while invading. Conversely, enhancing proliferation by overcoming p21CIP1 cell-cycle inhibition by growth promoting molecules such as active cyclin E (Trunk), suppressed tumor cell invasiveness both in vitro and in vivo. Furthermore, gene expression analysis showed that FGF-2 caused upregulation of invasion-mediating genes such as Snail, MMP-3, MMP-9, and downregulation of proliferation promoters including E2F-1 target genes (not shown). These data were further supported by microarray analysis of highly motile PyMT cells isolated from tumors in vivo, showing concomitant increase in migration and decrease in proliferation genes. 24 The effects in MCF-7 cells were reproduced in MCF10A, MDA-MB-231 and the 3475 metastatic variant, where silencing p21CIP1 enhanced proliferation and inhibited migration, implying a generalized effect on cellular behavior.
We investigated the role of p21CIP1 in vivo in the PyMT mammary tumor mouse as it represents a mammary tumor model with rapid onset and well-defined metastasis. 16, 25 Disruption of the p21CIP1 gene in this model eradicated lung metastasis, which was surprising in light of its putative tumor suppressive function. Although the aggregate tumor mass was attenuated in p21-knockout mice, this reduction was mild and unlikely to account for metastasis inhibition as knockout tumors did not spread at masses at which wild-type tumors were highly metastatic. Both our in vitro and in vivo data demonstrate that p21CIP1 suppresses metastasis by inhibiting tumor cell migration or invasion.
We speculate that p21CIP1 loss attenuates the tumor mass in vivo not by inhibiting tumor cell proliferation which was greater in p21-knockout carcinomas, but likely by limiting tumor 'self seeding'. 'Self-seeding' depends on tumor cell migration that 'seeds' tumor cells in the microenvironment to form foci which eventually grow and fuse into a large destructive mass. In addition, the primary tumor was shown to be helped by metastatic movement which returns cells back to the mass from the outside circulation, hence increasing tumor size. 26 Furthermore, p21CIP1 loss may limit tumor cells from chemotaxing toward blood vessels to access oxygen and nutrients for growth, suggesting a feedback loop between invasion and growth. In contrast to the PyMT/p21KO mouse, others have shown in an Apc-initiated mouse model of intestinal tumorigenesis that targeted inactivation of p21CIP1 enhances tumorigenesis. 27 However, since the intestine is devoid of stroma, this model precludes local invasion for growth regulation. Others have also shown that dependent on the oncogenic context, p21CIP1 deletion may produce opposite outcomes. In the context of the MMTV-Ras, p21CIP1 deficiency accelerated tumor onset, while in the MMTV-Myc mouse, it attenuated mammary tumor growth. 28 This appears to be due to differential effects of these oncogenes on cell-cycle progression as Myc is able to overcome G1 arrest independently of p21CIP1. 28 Thus, the oncogenic context influences the function of p21CIP1 as a growth inhibitor or promoter. One other possibility is that since p21CIP1 protects cells against DNA damage and ensued apoptosis, 4 its loss may enhance apoptosis and thus attenuates primary tumor growth or metastasis due to poor survival in the circulation. Our data did not however demonstrate apoptosis in knockout tumors relative to controls and hence do not support an anti-apoptotic effect of p21CIP1.
The suppressive effect of p21CIP1 loss on invasion and metastasis suggests that p21CIP1 may be regulating the motile machinery. However, most studies describing a pro-motile effect of p21CIP1 point to a cytoplasmic and not a nuclear form of p21CIP1, suggesting differential regulation of cellular function by p21CIP1 dependent on localization. Cytoplasmic p21CIP1 was shown to promote migration by inhibiting cofilin phosphorylation.
14 Another study in the MMTV-neu mouse implied that cytoplasmic p21CIP1 promotes tumorigenesis and metastasis. 13 Our findings however point to a predominantly nuclear p21CIP1 and do not indicate any changes in cofilin phosphorylation between PyMT/p21KO and PyMT tumor cells (Supplementary  Figure 2b) . Other studies implied that p27KIP1 promotes cell migration through RhoA activation, 29, 30 which would be compatible with the loss of stress fibers seen in PyMT/p21KO cells, if both CDKIs were to use RhoA to elicit stress fibers. 31, 32 However, p27KIP1 expression was unchanged and RhoA activity was undetected in PyMT or PyMT/p21KO cells, suggesting that p27KIP1 may not substitute for p21CIP1 in cell migration (not shown).
Underscoring a potentially complex role for p21CIP1 in metastasis, we surmize that beyond promoting cell-cycle arrest, p21CIP1 may directly regulate the EMT that accompanies metastasis. Indeed, p21CIP1 loss induced changes associated with ) cells into five athymic mice; lung foci were imaged or (g) counted at 3-12 weeks following injection. Data are the number of foci shown as mean±s.e.m., Po0.05 t-test.
p21CIP1 promotes mammary tumor metastasis X Qian et al epithelial differentiation. PyMT/p21-knockout tumor cells shifted from stress fibers to cortical actin, upregulated cytokeratins and gained cell polarity, consistent with the transition from a proliferative to a non-invasive state. In support of this idea, treatment of MCF10A with TGFb that induces EMT and migration, 15 increased p21CIP1 expression, enhanced invasiveness and decreased cell proliferation. During development, Snail upregulation in migratory neural crest cells was shown to cause increased p21CIP1 expression. 9 Whether p21CIP1 regulates EMT transcription factors to elicit EMT during metastasis remains to be determined.
Finally, it is possible that p21CIP1 knockout eliminates a basallike stem cell niche and hence eliminates metastasis. In support of a function in stem cell renewal, others have found p21CIP1 prevents DNA damage in leukemia stem cells, thus preserving the pool of the slowly proliferating leukemic stem cells. 33 Thus, p21CIP1 upregulation in tumors may select for cancer stem cell-like cells that are resistant to anti-mitotic therapy, thus contributing to the survival of a more aggressive or metastatic disease. Mouse mammary primary tumor cell lines Primary mammary tumors from PyMT and PyMT/p21KO mice were excised and rinsed in phosphate-buffered saline (PBS). Tumors were incubated in 10 ml of digestion media per gram of tissue (2 mg/ml Collagenase, 100 unit/ml Hyaluronidase, 100 units/ml penicillin/streptomycin, 2 mg/ml of bovine serum albumin in Medium 199) at 37 1C for 3 h. Digested material was centrifuged at 1000 r.p.m. for 5 min. Pelleted cells were plated at 1 Â 10 7 cells per 10 cm dish in DMEM/10% fetal bovine serum including 10 mg/l insulin and 10 ng/ml EGF. Fibroblasts were depleted from cultures by limiting trypsinization. Epithelial cells were grown in culture for limited passages.
MATERIALS AND METHODS
DNA constructs and reagents
The activated cyclin E construct, known as 'Trunk', was provided by Dr Khandan Keymorsi (University of Texas, MD Anderson Cancer Center, Houston, TX, USA). p21CIP1 expression vector was obtained from Dr Stuart Aaronson (Mount Sinai School of Medicine, New York, NY, USA). p21CIP1 siRNA and control siRNA were obtained from Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA). Stable RNAi-mediated suppression of p21CIP expression was performed using four shRNA-expressing lentiviral constructs targeting human CDKN1A (NM_000389; Thermo Scientific, Huntsville, AL, USA). These include V2LHS_202469 (Hs shp21-1), V2LHS_230370 (Hs sh p21-2), V2LHS_322231 (Hs shp21-3) and V2LHS_322232 (Hs shp21shRNA-4). V3LMM_500307 (Mm shp21) targeting mouse CDKN1A (NM_001111099) was utilized to exclude non-specificity and a non-silencing-GIPZ lentiviral shRNA (Thermo Scientific, #RHS4346) was used as control vector. The p21CIP1 promoter luciferase reporter construct was obtained from Dr Phillis Luvalle (University of Calgary, Canada).
Real-time PCR
RNA was isolated using Trizol reagent (Invitrogen) following manufacturer's protocol. Human and murine p21CIP1 Taqman primers and RNA-to-CT 1-Step Kit were obtained from Applied Biosystems (Carlsbad, CA, USA). Real-time PCR experiments were performed according to manufacturer's protocol using a StepOnePlus real-time PCR instrument from Applied Biosystems. GAPDH was used as the reference gene and relative mRNA levels were determined using the 2 ( À DDCt) method. Three independent experiments were performed. Statistical significance was calculated using the two-tailed t-test, Po0.05.
Luciferase assay
The activity of the p21CIP1 promoter was measured by transient transfection into MCF-7 and MCF-7-N-cad cells of the reporter plasmid pG1 p21 H2320 containing 2320 nucleotides of the human p21CIP1 promoter fused to the firefly luciferase reporter gene. Luciferase assays were performed with the Dual Luciferase Assay Kit (Promega, Madison, WI, USA) according to manufacturer's protocol using a luminometer (Promega).
Antibodies and growth factors
Antibodies against p21CIP1, p27KIP1 and cyclin E were obtained from Santa Cruz Biotechnology Inc. Mouse monoclonal anti E-cadherin, N-cadherin and FITC-conjugated anti-BrdU were from BD Biosciences (Bedford, MA, USA). Mouse monoclonal anti vinculin, rabbit polyclonal anti ZO-1, Alexafluor 594 phalloidin were from Invitrogen. Mouse antibodies against pan-cytokeratin, BrdU, a-tubulin or b-actin were from Sigma. Secondary antibodies (FITC or TRITC labeled) were purchased from Invitrogen, and HRP conjugates were from Amersham (Pittsburg, PA, USA). FGF-2, EGF and TGFb were from Peprotech Inc (Princeton, NJ, USA).
Immunoblotting
Cells or tissues were extracted in solubilization buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM MgCl 2 , 0.2 mM EGTA, 1% Triton X-100) including protease inhibitors. For detection of p21CIP1, cells were extracted in solubilization buffer including 1% SDS and sonicated. Thirty micrograms protein were loaded on 7-12% SDS-polyacrylamide gels and transferred onto Immobilon membranes. Blots were probed overnight at 4 1C with indicated antibodies and developed by chemiluminescence using ECL detection reagents (Pierce, Thermo Scientific, Rockford, IL, USA).
Immmunofluorescence
Cells were plated on coverslips, fixed in 3.7% paraformaldehyde for 30 min at room temperature. Cells were permeabilized for 2 min in 0.01% Triton X-100, washed in PBS, and blocked in 2% bovine serum albumin in PBS for 1 h. Cells were incubated with 2 mg/ml of primary antibody in PBS/0.5% bovine serum albumin, washed and incubated with 1:5000 FITC-or TRITCconjugated secondary antibodies for 1 h. Cells were then washed and counterstained in DAPI to visualize nuclei. Fluorescence and bright field images were captured using a Zeiss Axioskop 2 plus upright microscope (Zeiss, Thornwood, NY, USA) fitted either with the Axiocam MRm (monochrome) or MRc (color) CCD cameras.
Cell migration and invasion assays
Cell migration or invasion was analyzed using a Boyden chamber as outlined. 34 Briefly, 24-well culture plates fitted with Transwell filters at 8 mm thickness were coated with 5-20 mg Matrigel for invasion assays or left uncoated for migration assays. Fibroblast conditioned medium was used as the chemoattractant in the lower compartment of the Boyden chamber. Single-cell suspensions were plated at 1 Â 10 5 cells in 0.5 ml DME, 0.1% bovine serum albumin per well into the upper chamber for 5-18 h. Cells on top the filters were removed and cells penetrating the filters were stained with 0.5% crystal violet or DAPI for counting cell nuclei. Invaded or migrated cells were expressed as the average number of migrated cells per microscopic field over four fields per assay in triplicate experiments. Statistical significance was determined by one-tailed t-test, Po0.05.
Time lapse cell motility
Subconfluent MDA-231 or 3475 cells were transfected with control or p21CIP1 siRNA and were grown on glass bottomed imaging dishes (MatTek Corp., Ashland, MA, USA). Cells were incubated in DMEM/25 mM Hepes and mounted on the stage of a semi-motorized Axio-Observer D1 Zeiss microscope (Zeiss). Images were obtained at 1 min intervals for 30 min using a Â 40 oil lens and the Axiovision Rel 4.7 program (Zeiss, Munich, Germany). Lengths of the cellular processes were determined at each time point for 30 min in response to 50 ng/ml EGF, and the changes were presented as outgrowth/retraction of cellular processes (mm) in function of time. This quantifies the process of attachment and detachment, necessary for movement of the cells in response to EGF. In addition, we determined the distance of migration of the cells from the starting point to the place where the cells moved in a period of 30 min (average distance/mm). To quantify the length of the cellular processes and the movement of the cells, an imaging software was used, NIS elements from Nikon (Tokyo, Japan) and Axiovision Rel. 4.7.
Mouse breeding
Mice were housed and maintained by the Animal Studies Institute at the Albert Einstein College of Medicine. Animal protocols used for this study were reviewed and approved by the Institute for Animal Studies. MMTVPyMT and p21knockout (p21KO) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). PyMT/p21KO mice were derived by brother-sister (sibling) mating of progeny from a cross of p21KO female (Bl6/ 129S/background) with MMTV-PyMT heterozygous male (FVB background). The F2 progeny of selected brother-sister matings was genotyped. Mice were identified for PyMT and p21CIP1 status by tail PCR using a primer set for PyMT: 5 0 -GGAAGCAAGTACTTCACAAGGG-3 0 and 5 0 -GGAAAGTCACTAG GAGCAGGG-3 0 , a primer set for wild-type p21: 5 0 -AAGCCTTGATTCTGAT GTGGGC-3 0 and 5 0 -TGACGAAGTCAAAGTTCCACC-3 0 , and a primer set to detect p21 nullizygous mice 5 0 -AAGCCTTGATTCTGATGTGGGC-3 0 and 5 0 -GCTATCAGGACATAGCGTTGGC-3 0 . Transgenic animals were identified by the presence of a distinct 556 bp product for PyMT, an 872-bp fragment for wildtype p21 and a 700-bp fragment for nullizygous mice. These resulting recombinant mice were on a mixed Bl6/129S/FVB/N background. Female PyMT þ / À /p21 þ / þ and PyMT þ / À /p21 À / À mice were used in the tumor study and were of identical mixed genetic background.
Tumor growth kinetics
Total tumor mass (all tumors and mammary gland remnants) was determined in at least 10 mice at 0 (onset), 0, 4, 6, 8, 10 and 13 weeks post primary tumor onset that occurred at 12 weeks after birth. 34 Aggregate tumor mass was displayed as mean ± s.e.m. Statistical analyses were performed comparing individual time points using the MannWhitney U-test and significant differences were established at Po0.005. p21CIP1 promotes mammary tumor metastasis X Qian et al
